Filing Details
- Accession Number:
- 0001493152-21-028917
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-11-16 15:09:58
- Reporting Period:
- 2021-10-18
- Accepted Time:
- 2021-11-16 15:09:58
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1833214 | Sab Biotherapeutics Inc. | SABS | Biological Products, (No Disgnostic Substances) (2836) | 853899721 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1889754 | P Russell Beyer | 2100 E 54Th Street North Sioux Falls SD 57104 | Chief Financial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2021-10-18 | 2,475 | $10.10 | 2,475 | No | 4 | A | Direct | |
Common Stock | Acquisiton | 2021-09-28 | 149 | $10.08 | 149 | No | 4 | A | Indirect | By spouse |
Common Stock | Acquisiton | 2021-10-25 | 129 | $7.78 | 278 | No | 4 | A | Indirect | By spouse |
Common Stock | Disposition | 2021-10-26 | 278 | $7.90 | 0 | No | 4 | S | Indirect | By spouse |
Common Stock | Acquisiton | 2021-09-28 | 5 | $10.07 | 5 | No | 4 | A | Indirect | By daughter |
Common Stock | Acquisiton | 2021-09-29 | 10 | $10.08 | 15 | No | 4 | A | Indirect | By daughter |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | A | Direct | |
No | 4 | A | Indirect | By spouse |
No | 4 | A | Indirect | By spouse |
No | 4 | S | Indirect | By spouse |
No | 4 | A | Indirect | By daughter |
No | 4 | A | Indirect | By daughter |
Footnotes
- This transaction occurred prior to the business combination pursuant to the Agreement and Plan of Merger, dated June 21, 2021 and as amended August 12, 2021, by and among Big Cypress Acquisition Corp., Big Cypress Merger Sub Inc., and SAB Biotherapeutics, Inc. ("Issuer"). The reporting person's obligation to disclose this transaction occurred upon the consummation of the business combination.
- The sale of Issuer common stock by the reporting person's spouse reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 278 shares, with the purchase of 278 shares of Issuer's common stock as also reported herein. The reporting person has paid to Issuer, upon settlement of the sale, $15.48, representing the full amount of the profit realized in connection with the short-swing transaction.